S. Cedrés

4.3k citations

80 papers · 2.2k indexed · 1 hit paper · h-index 20

Impact in

Oncology top 2%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Inflammatory Biomarkers in Disease Prognosis
Pulmonary and Respiratory Medicine top 2%
- Occupational and environmental lung diseases
- Lung Cancer Treatments and Mutations
- Pleural and Pulmonary Diseases
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

Papers in ⓘ

Pulmonary and Respiratory Medicine 67
- Lung Cancer Treatments and Mutations 31
- Occupational and environmental lung diseases 30
- Pleural and Pulmonary Diseases 18
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis 11
Oncology 42
- Cancer Immunotherapy and Biomarkers 18
- Lung Cancer Research Studies 13

Co-authors: Enriqueta Felip (53 shared papers)Pablo Martínez (17 shared papers)Alejandro Navarro (33 shared papers)Alex Martínez‐Martí (27 shared papers)Davis Y. Torrejon (5 shared papers)Joachim G.J.V. Aerts (7 shared papers)Esther Zamora (5 shared papers)Núria Pardo (21 shared papers)
Journals: Journal of Clinical Oncology (17 papers)Annals of Oncology (10 papers)Lung Cancer (7 papers)Clinical & Translational Oncology (6 papers)Journal of Thoracic Oncology (5 papers)
Partner nations: Spain Palestinian Territory France

In The Last Decade

S. Cedrés

73 papers receiving 2.2k citations

Hit Papers

align trajectories log scale

Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial 2017 · 304 citations

Peers

Countries citing papers authored by S. Cedrés

Since Specialization

Citations

This map shows the geographic impact of S. Cedrés's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Cedrés with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Cedrés more than expected).

Fields of papers citing papers by S. Cedrés

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Cedrés. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Cedrés. The network helps show where S. Cedrés may publish in the future.

Co-authors

The 25 scholars most cited alongside S. Cedrés, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with S. Cedrés Line = papers co-authored together S. Cedrés links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 80 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial The Lancet Oncology ·Michele Maio, Arnaud Scherpereel, Luana Calabrò, Joachim G.J.V. Aerts, S. Cedrés, Alessandra Bearz, Kristiaan Nackaerts, Dean A. Fennell, Dariusz M. Kowalski, Anne S. Tsao, Paul Taylor, Federica Grosso, Scott Antonia, Anna K. Nowak, Maria Taboada, M. Puglisi, Paul K. Stockman, Hedy L. Kindler Hit paper breakdown →	2017	304
2	Immune-Related Gene Expression Profiling After PD-1 Blockade in Non–Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma Cancer Research ·Aleix Prat, Alejandro Navarro, Laia Paré, Noemı́ Reguart, Patricia Galván, Tomás Pascual, Alex Martínez‐Martí, Paolo Nucíforo, Laura Comerma, Llúcia Alós, Núria Pardo, S. Cedrés, Cheng Fan, Joel S. Parker, Lydia Gaba, Iván Victoria, Núria Viñolas, Ana Vivancos, Ana Arance, Enriqueta Felip	2017	277
3	Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer Clinical & Translational Oncology ·S. Cedrés, Davis Y. Torrejon, A. Martínez, Pablo Martínez, Alejandro Navarro, Esther Zamora, N. Mulet-Margalef, Enriqueta Felip	2012	224
4	Serum Tumor Markers CEA, CYFRA21-1, and CA-125 Are Associated With Worse Prognosis In Advanced Non–Small-Cell Lung Cancer (NSCLC) Clinical Lung Cancer ·S. Cedrés, Isaac Núñez, Marina Longo, Pablo Martínez, Eva Checa, Davis Y. Torrejon, Enriqueta Felip	2011	166
5	Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM) PLoS ONE ·S. Cedrés, Santiago Ponce-Aix, Jon Zugazagoitia, Irene Sansano, Ana B. Enguita, Alejandro Navarro, Alex Martínez‐Martí, Pablo Martínez, Enriqueta Felip	2015	146
6	Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial The Lancet Oncology ·Giovanni Luca Ceresoli, Joachim G.J.V. Aerts, Rafał Dziadziuszko, Rodryg Ramlau, S. Cedrés, Jan P. van Meerbeeck, Manlio Mencoboni, David Planchard, Antonio Chella, Lucio Crinò, Maciej Krzakowski, Jörn Rüssel, Antonio Maconi, Letizia Gianoncelli, Federica Grosso	2019	107
7	Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND—A Double-Blind, Randomized, Phase II Study Journal of Clinical Oncology ·Dean A. Fennell, Paul Baas, Paul Taylor, Anna K. Nowak, David Gilligan, Takashi Nakano, Jonathan A. Pachter, David T. Weaver, Arnaud Scherpereel, Nick Pavlakis, Jan P. van Meerbeeck, S. Cedrés, Luke Nolan, Hedy L. Kindler, Joachim G.J.V. Aerts	2019	83
8	Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumab‐based therapy Head & Neck ·Aleix Prat, Marta Parera, Vicky Reyes, Sergio Peralta, S. Cedrés, Jordi Andreu, Pere Huguet, J.M. del Campo	2007	77
9	A Phase II Pharmacodynamic Study of Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy Clinical Cancer Research ·Enriqueta Felip, Federico Rojo, Martin Reck, Astrid Heller, Barbara Klughammer, Gemma Laguillo Sala, S. Cedrés, Sergio Peralta, Heiko Maacke, Dorothee Foernzler, Marta Parera, Joachim Möcks, Cristina Saura, U. Gatzemeier, José Baselga	2008	68
10	Fluorescence In Situ Hybridization and Immunohistochemistry as Diagnostic Methods for ALK Positive Non-Small Cell Lung Cancer Patients PLoS ONE ·Pablo Martínez, Javier Hernández‐Losa, (unknown), S. Cedrés, Josep Castellví, Alex Martínez‐Martí, N Tallada, Núria Murtra Garrell, Alejandro Navarro-Mendivill, Víctor Rodríguez-Freixinós, Mercedes Canela, Santiago Ramón y Cajal, Enriqueta Felip	2013	55
11	DualMET andERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC) Annals of Oncology ·Alex Martínez‐Martí, Enriqueta Felip, Judit Matito, Elisabetta Mereu, Alejandro Navarro, S. Cedrés, Núria Pardo, A. Martinez de Castro, Jordi Remón, Josep M. Miquel, Amy Guillaumet-Adkins, Ernest Nadal, Gustavo Rodríguez-Esteban, Oriol Arqués, Roberta Fasani, Paolo Nucíforo, Holger Heyn, Alberto Villanueva, Héctor G. Pálmer, Ana Vivancos	2017	55
12	Exploratory analysis of activation of PTEN–PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM) Lung Cancer ·S. Cedrés, M. A. Montero, Pablo Martínez, Alex Martínez‐Martí, Víctor Rodríguez-Freixinós, Davis Y. Torrejon, Alejandra Gabaldón, M.T. Allende, Santiago Ramón y Cajal, Enriqueta Felip	2012	55
13	Overview of Checkpoint Inhibitors Mechanism of Action: Role of Immune-Related Adverse Events and Their Treatment on Progression of Underlying Cancer Frontiers in Medicine ·Patricia Iranzo, Ana Callejo, J.D. Assaf, Gaspar Molina, D. López-Valbuena, David García-Illescas, Núria Pardo, Alejandro Navarro, Alex Martínez‐Martí, S. Cedrés, Caterina Carbonell, Joan Frigola, Ramon Amat, Enriqueta Felip	2022	53
14	Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: A phase I dose-escalation study Lung Cancer ·Martin Reck, Norbert Frickhofen, S. Cedrés, U. Gatzemeier, David F. Heigener, H. G. Fuhr, Aron D. Thall, Silvana Lanzalone, Patricia Stephenson, Ana Ruiz-Garcı́a, Richard C. Chao, Enriqueta Felip	2010	38
15	Analysis of expression of PTEN/PI3K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM) Lung Cancer ·S. Cedrés, Santiago Ponce-Aix, Nuria Pardo-Aranda, Alejandro Navarro, Alex Martínez‐Martí, Jon Zugazagoitia, Irene Sansano, M.A. Montoro, Ana B. Enguita, Enriqueta Felip	2016	31
16	Tremelimumab as second- or third-line treatment of unresectable malignant mesothelioma (MM): Results from the global, double-blind, placebo-controlled DETERMINE study. Journal of Clinical Oncology ·Hedy L. Kindler, Arnaud Scherpereel, Luana Calabrò, Joachim G.J.V. Aerts, S. Cedrés, Alessandra Bearz, Kristiaan Nackaerts, Dean A. Fennell, Dariusz M. Kowalski, Anne S. Tsao, Paul Taylor, Federica Grosso, Scott Antonia, Anna K. Nowak, Ramy Ibrahim, Maria Taboada, M. Puglisi, Paul K. Stockman, Michele Maio	2016	31
17	Molecular profiling of long‐term responders to immune checkpoint inhibitors in advanced non‐small cell lung cancer Molecular Oncology ·Joan Frigola, Alejandro Navarro, Caterina Carbonell, Ana Callejo, Patricia Iranzo, S. Cedrés, Alex Martínez‐Martí, Núria Pardo, (unknown), Eduardo Martínez de Dueñas, José Jiménez, Irene Sansano, Francesco M. Mancuso, Paolo Nucíforo, Luis M. Montuenga, Montse Sánchez‐Céspedes, Aleix Prat, Ana Vivancos, Enriqueta Felip, Ramon Amat	2020	27
18	Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches Lung Cancer ·Jordi Remón, Núria Pardo, Alex Martínez‐Martí, S. Cedrés, Alejandro Navarro, Ana Castro, Enriqueta Felip	2017	25
19	NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma Journal of Translational Medicine ·Vilde Drageset Haakensen, Anna K. Nowak, Espen B. Ellingsen, S.J. Farooqi, Maria Moksnes Bjaanæs, Henrik Horndalsveen, Tine McCulloch, Oscar Grundberg, S. Cedrés, Åslaug Helland	2021	21
20	Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial ESMO Open ·Nicolas Girard, Santiago Ponce Aix, S. Cedrés, Thierry Berghmans, Sjaak Burgers, A.C. Toffart, Sanjay Popat, Annelies Janssens, R. Gervais, M. Hochstenbag, Mario Silva, Irene A. Burger, Helmut Prosch, Rolf A. Stahel, Eleni Xenophontos, Y. Pretzenbaher, Anouk Neven, Solange Peters	2023	19

About S. Cedrés

S. Cedrés is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Biotechnology, Cancer Research and Hepatology, having authored 80 papers that have together received 2.2k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (31 papers), Occupational and environmental lung diseases (30 papers), Pleural and Pulmonary Diseases (18 papers), Cancer Immunotherapy and Biomarkers (18 papers), Lung Cancer Research Studies (13 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (11 papers), Cancer Research and Treatments (11 papers) and Cancer Genomics and Diagnostics (10 papers). The work is most often cited by research in Oncology (1.3k citations), Pulmonary and Respiratory Medicine (1.2k citations), Biotechnology (164 citations), Cancer Research (272 citations) and Immunology (305 citations). S. Cedrés has collaborated with scholars based in Spain, Palestinian Territory and France. Frequent co-authors include Enriqueta Felip, Pablo Martínez, Alejandro Navarro, Alex Martínez‐Martí, Davis Y. Torrejon, Joachim G.J.V. Aerts, Esther Zamora, Núria Pardo, Aleix Prat and Federica Grosso. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Lung Cancer, Clinical & Translational Oncology and Journal of Thoracic Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact